Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

NCT03348514 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: CPX-POM - 30 mg/m^2
DRUG: CPX-POM - 60 mg/m^2
DRUG: CPX-POM - 120 mg/m^2
DRUG: CPX-POM - 240 mg/m^2
DRUG: CPX-POM - 360 mg/m^2
DRUG: CPX-POM - 600 mg/m^2
DRUG: CPX-POM - 900 mg/m^2
DRUG: CPX-POM - 1200 mg/m^2

Sponsor

CicloMed LLC

Collaborators

[object Object]